{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:43Z","timestamp":1760189503859},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Peripheral T-cell lymphomas (PTCL), with the exception of anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), have a very poor prognosis. Although current first line chemotherapy continues to be a CHOP-like (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen there is now data suggesting that the addition of etoposide in younger patients improves outcomes. Even for those patients who do have a response to therapy, the risk of relapse remains quite high. Although autologous transplant in first remission is often used, its role as consolidation therapy in first remission remains unclear and may preferentially benefit low-risk patients. In the relapsed setting, major advances have occurred with Food and Drug Administration (FDA) approval of 4 new agents (pralatrexate, romidepsin, belinostat, brentuximab vedotin) for relapsed\/refractory PTCL since 2009. These 4 drugs represent the first agents ever approved specifically for this indication. Unfortunately, with the exception of ALCL for which brentuximab vedotin will likely substantially change our approach to treatment, there are still many patients for whom available drugs will not be effective, and it is for these patients that further advances are urgently needed.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.550","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"550-558","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma"],"prefix":"10.1182","volume":"2015","author":[{"given":"Anne W.","family":"Beaven","sequence":"first","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis F.","family":"Diehl","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, NC"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"12","key":"2019111708591507500_B1","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2019111708591507500_B2","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2019111708591507500_B3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111708591507500_B4","article-title":"WHO Classificaiton of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008","edition":"Ed 4"},{"issue":"7","key":"2019111708591507500_B5","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"issue":"1-2","key":"2019111708591507500_B6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10428199609045720","article-title":"Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas","volume":"24","author":"Karakas","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"2019111708591507500_B7","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2019111708591507500_B8","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111708591507500_B9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111708591507500_B10","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111708591507500_B11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"key":"2019111708591507500_B12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8507","article-title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): results from the BELIEF trial","volume":"31","author":"O'Connor","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111708591507500_B13","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111708591507500_B14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111708591507500_B15","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"issue":"18","key":"2019111708591507500_B16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111708591507500_B17","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"2019111708591507500_B18","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"20","key":"2019111708591507500_B19","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"2019111708591507500_B20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","article-title":"Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses","volume":"7","author":"Coiffier","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"6","key":"2019111708591507500_B21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00277-015-2309-z","article-title":"Modified ESHAP regimen for relapsed\/refractory T cell lymphoma: a retrospective analysis","volume":"94","author":"Kogure","year":"2015","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111708591507500_B22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"2019111708591507500_B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.4345.4345","article-title":"Gemcitabine, dexamethasone, and cisplatin (GDP) as secondary chemotherapy in relapsed\/refractory peripheral T cell lymphoma","volume":"122","author":"Parkin","year":"2013","journal-title":"Blood"},{"key":"2019111708591507500_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2679.2679","article-title":"Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed\/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat","volume":"106","author":"Horwitz","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111708591507500_B25","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3109\/10428194.2011.569038","article-title":"Multicenter study of comparative outcomes of hematopoietic stem cell transplant for peripheral T cell lymphoma and natural killer\/T-cell lymphoma","volume":"52","author":"Hwang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2019111708591507500_B26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","article-title":"The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study","volume":"40","author":"Feyler","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2019111708591507500_B27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","article-title":"Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease","volume":"21","author":"Beitinjaneh","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2019111708591507500_B28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00277-002-0556-2","article-title":"Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation","volume":"81","author":"Kahl","year":"2002","journal-title":"Ann Hematol"},{"issue":"17","key":"2019111708591507500_B29","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111708591507500_B30","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","article-title":"Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111708591507500_B31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111708591507500_B32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"issue":"22","key":"2019111708591507500_B33","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111708591507500_B34","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"2019111708591507500_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1763.1763","article-title":"A phase II open-label, multi-center study of anti-CCR4 monoclonal antibody mogamulizumab (KW-0761) in patients with previously treated peripheral T-cell lymphoma (PTCL)","volume":"124","author":"Zinzani","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111708591507500_B36","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1365-2141.2003.04311.x","article-title":"Aurora2\/BTAK\/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin's lymphoma","volume":"121","author":"Hamada","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111708591507500_B37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111708591507500_B38","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1200\/JCO.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J Clin Oncol"},{"key":"2019111708591507500_B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase \u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"28","key":"2019111708591507500_B40","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"key":"2019111708591507500_B41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.504.504","article-title":"Final analysis of the RO-CHOP phase Ib\/II study: romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL)","volume":"124","author":"Dupuis","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111708591507500_B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.3044.3044","article-title":"A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): Preliminary results from the T-Cell consortium trial","volume":"122","author":"Advani","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2019111708591507500_B43","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"issue":"5","key":"2019111708591507500_B44","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"issue":"1","key":"2019111708591507500_B45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/550\/1251359\/bep00115000550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/550\/1251359\/bep00115000550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T01:51:47Z","timestamp":1601085107000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/550\/20748\/Peripheral-Tcell-lymphoma-NOS-and-anaplastic-large"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.550","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}